COCP - Company ID 0001412486
The table below shows Cocrystal Pharma, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$8.19M | -$16.48M | -$14.67M | -$21.43M | -$12.72M | -$9.83M |
| Capital expenditure | $12.00K | $8.00K | $118.00K | $74.00K | $52.00K | $240.00K |
| Investing cash flow | -$12.00K | -$8.00K | -$118.00K | -$74.00K | -$52.00K | -$240.00K |
| Dividends paid | - | - | - |
Cocrystal Pharma, Inc. reported operating cash flow of -$8.19M for fiscal year 2025. That is up 50.3% from -$16.48M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$14.65M (FY 2016) to -$8.19M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $5.37M | - | $3.99M | -$27.00K | $38.47M | $35.66M |